

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.:	APPLICATION NO.:
	15741.004	10/754,547
Sheet 1 of 2	APPLICANT:	
	Longgui WANG et al.	
	FILING DATE:	GROUP:
	January 12, 2004	1614

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1							
	B2							

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
C5	Franceschi, C. et al., "Inflamm-aging. An Evolutionary Perspective on Immunosenescence", <i>Ann N Y Acad Sci</i> , 908 :244-254 (2000).	
C6	Group, C., "Phase I Clinical Trial on Meisoindigo in the Treatment of Chronic Myelogenous Leukemia", <i>J. Chinese Hematology</i> , 18 :69-72 (1997) (Abstract only)	
C7	Ito, Hiroaki, "IL-6 and Crohn's Disease", <i>Current Drug Targets – Inflammation & Allergy</i> , 2 :125-130 (2003).	
C8	Ito, T. et al., "Inflammatory Cytokines and Cardiovascular Disease", <i>Current Drug Targets – Inflammation & Allergy</i> , 2 :257-265 (2003).	
C9	Koo, J. et al., "Traditional Chinese Medicine in Dermatology", <i>Dermatologic Therapy</i> , 16(2) :98-105 (2003).	
C10	Koo, J. et al., "Traditional Chinese Medicine for the Treatment of Dermatologic Disorders", <i>Arch Dermatol.</i> , 134 :1388-1393 (November 1998).	
C11	Lahiri, D.K., et al., "Role of Cytokines in the Gene Expression of Amyloid β -protein Precursor: Identification of a 5'-UTR-Binding Nuclear factor and Its Implications in Alzheimer's Disease", <i>Journal of Alzheimer's Disease</i> , 5 :81-90 (2003).	
C12	Lichtiger, S. et al., "Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy", <i>New England Journal of Medicine</i> , 330(26) :1841-1845 (June 30, 1994).	
C13	Lin et al., "Meisoindigo for Psoriasis Treatment", <i>Chinese Journal of Dermatology</i> , 22(1) :29-30 (1989).	
C14	Maccarrone, M. et al., "Endocannabinoid Degradation, Endotoxic Shock and Inflammation", <i>Current Drug Targets – Inflammation & Allergy</i> , 1 :53-63 (2002).	

EXAMINER PHX/1963434.1/15741.004	DATE CONSIDERED
--	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.:	APPLICATION NO.:
	15741.004	10/754,547
Sheet 2 of 2	APPLICANT:	
	Longgui WANG et al.	
	FILING DATE:	GROUP:
	January 12, 2004	1614

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	C15	Murthy, S. et al., "The Efficacy of BAY y 1015 in Dextran Sulfate Model of Mouse Colitis", <i>Inflamm. Res.</i> , 46 :224-233 (1997).
	C16	Murthy, S. et al., "Treatment of Dextran Sulfate Sodium-Induced Murine Colitis by Intracolonic Cyclosporin", <i>Digestive Diseases and Sciences</i> , 38(9) :1722-1734 (September 1993).
	C17	Rogers, J. et al., "A Perspective on Inflammation in Alzheimer's Disease", <i>Ann N Y Acad Sci</i> , 924 :132-135 (2000).
	C18	Weinberg, J. et al., "Biologic Therapy for Psoriasis – The First Wave: Infliximab, Etanercept, Efalizumab, and Alefacept", <i>J. Drugs Dermatol</i> , 3 :303-310 (2002).
	C19	Zhang, H. et al., "Advances in Experimental Studies on Treatment of Psoriasis by Traditional Chinese Medicine", <i>J Tradit Chin Med</i> , 22(1) :61-66 (March 2002) (Abstract only).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./

EXAMINER PHX/1963434.1/15741.004 /Donna Jagoe/	DATE CONSIDERED 04/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 . Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	